Sajid Khan, Ph.D., M.Sc.

Google Scholar

My Bibliography  

1. Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim Y-M, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine. 2019, 25:1938–1947. PMCID: PMC6898785
2. Khan S*, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discovery. 2023 Jan 2;9(1):1. (*corresponding author). PMCID: PMC9806104
3. Khan S*, Weigand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D*. A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors in preclinical models of KRASG12C–mutated cancers. Journal of Hematology & Oncology. 2022, 15:23. (*co-corresponding author). PMCID: PMC8905794
4. Thummuri D*, Khan S*, Underwood PU*, Zheng P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe C, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL Specific Degrader DT2216. Molecular Cancer Therapeutics. 2022, 21:184-192. (*co-first author). PMCID: PMC8742767
5. Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei P, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen S, Weintraub S, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature Communications. 2021,12:6896. PMCID: PMC8617031
6. Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar S, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. Journal of Medicinal Chemistry. 2021, 64:14230-14246. PMCID: PMC8900268
7. Kolb R, De U, Khan S, Luo Y, Kim M-C, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu Y-X, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature Communications. 2021, 2:1281. PMCID: PMC7904819
8. Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as Emerging Anticancer Therapeutics. Oncogene, 2020, 39:4909-4924. PMCID: PMC7319888
9. He Y*, Khan S*, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology & Oncology. 2020, 13:103. PMCID: PMC7384229. (*co-first author)
10. He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology. 2020, 13:95. PMCID: PMC7364785
11. Khan S, Shukla S, Sinha S, Meeran SM. Centchroman altered the expressions of tumor‐related genes through active chromatin modifications in mammary cancer. Molecular Carcinogenesis. 2016, 55:1747-1760.
12. Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. The International Journal of Biochemistry & Cell Biology. 2015, 58:1-16.
13. Dighe SU*, Khan S*, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S.  Synthesis of β- Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells. Journal of Medicinal Chemistry. 2015; 58:3485–99. (*co-first author)
14. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets. Cytokine & Growth Factor Reviews. 2013, 24(6):503-13.